4 – Alzheimers

The Alzheimer’s Association announced in July that the FDA had accepted its recommendations to modify exclusion and monitoring criteria for clinical trials of agents that affect ?-amyloid protein in the brain.

Original post:
Alzheimer’s Association Prompts FDA to Broaden Trials